What is the 13F Pro Quality Score for JAZZ?

13F Pro ranks Jazz Pharmaceuticals plc (JAZZ) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View JAZZ's current score at https://13fpro.ai/company/JAZZ (free sign-up required for the full ranking).

Which hedge funds own the most JAZZ stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of JAZZ include BlackRock,, FMR, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/JAZZ as soon as new 13F filings post.

Where does 13F Pro source JAZZ data?

All Jazz Pharmaceuticals plc fundamentals and ownership data come directly from SEC EDGAR. Jazz Pharmaceuticals plc files with the SEC under CIK 1232524. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is JAZZ in?

Jazz Pharmaceuticals plc (JAZZ) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives JAZZ's revenue?

Per Jazz Pharmaceuticals plc's latest 10-Q filed with the SEC on 2026-08-03, the biggest revenue drivers are: Sleep disorders (Xywav, Xyrem) ($941.1M, +13% YoY); Epilepsy (Epidiolex/Epidyolex) ($541.9M, +15% YoY); Oncology ($695.7M, +38% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/JAZZ.

What are JAZZ's largest expenses?

Jazz Pharmaceuticals plc's latest 10-Q reports these as the largest expense items: Research and development ($403.5M, +9% YoY); Selling, general and administrative ($741.9M, -15% YoY); Intangible asset amortization ($342.3M, +8% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (six months ended June 30, 2026).

How often is JAZZ research updated on 13F Pro?

JAZZ's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Jazz Pharmaceuticals plc(JAZZ)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1232524 JAZZ stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

70.8/100

Rank #208 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why JAZZ Scores 71/100

exact factor attribution · 2026-09-11

JAZZ's composite is driven by free cash flow and profitability, held back by institutional flow and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Free cash flow

+5.7 pts

88th pct

Profitability

+5.2 pts

85th pct

Scale

+3.8 pts

76th pct

Capital efficiency

+3.2 pts

82th pct

Earnings quality

+3.0 pts

80th pct

Earnings growth

+1.9 pts

87th pct

Revenue growth

+1.5 pts

58th pct

Shareholder dilution

-1.5 pts

20th pct

Institutional flow

-2.0 pts

10th pct

Latest change (2026-08-05): 67 → 71 · ↑ Profit margin 78→88; ↑ Capital efficiency 72→83

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

JAZZ Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Jazz Pharmaceuticals plc (JAZZ), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores JAZZ at 70.8/100 on a 32-signal composite quality model, placing it at rank #208 of 2,961 stocks — the top 10% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Jazz Pharmaceuticals plc reports quarterly revenue of $1.2B, net income of $192.8M, free cash flow of $397.6M. Top institutional holders of JAZZ by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. JAZZ trades on the Nasdaq exchange and files with the SEC under CIK 1232524. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JAZZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jazz Pharmaceuticals plc directly from SEC EDGAR. Jazz Pharmaceuticals plc's 13F Pro composite quality score has ranged between 54 and 71 since 2026, currently 70.8 — an improving long-term trajectory across 49 quarterly and live scoring snapshots.

What's Driving JAZZ's Business? Latest 10-Q Breakdown

AI-extracted from Jazz Pharmaceuticals plc's 10-Q filed 2026-08-03 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Jazz Pharmaceuticals reported H1 2026 total revenues of $2.28B (+17% YoY), driven by Xywav growth of +16% YoY and oncology revenue expansion of +38% YoY, with operating income of $584.8M versus loss of $742.3M in prior year.

Biggest Revenue Drivers

Sleep disorders (Xywav, Xyrem)$941.1M+13% YoY

Xywav volume growth of 12% and higher selling price; narcolepsy patients increased 6% to 11,275; idiopathic hypersomnia patients increased 26% to 5,850.

Epilepsy (Epidiolex/Epidyolex)$541.9M+15% YoY

Volume growth of 13% driven by increased demand and higher average selling price, partially offset by higher deductions.

Biggest Revenue Drivers

Total revenue: $2.28B+17% YoY

Sleep disorders (Xywav, Xyrem)$941.1M+13% YoY

Xywav volume growth of 12% and higher selling price; narcolepsy patients increased 6% to 11,275; idiopathic hypersomnia patients increased 26% to 5,850.

Epilepsy (Epidiolex/Epidyolex)$541.9M+15% YoY

Volume growth of 13% driven by increased demand and higher average selling price, partially offset by higher deductions.

Oncology$695.7M+38% YoY

Zepzelca +50% YoY on adoption in first-line maintenance setting; Modeyso contributed $89.6M post-launch in August 2025; Ziihera +157% on launch in December 2024.

Royalties and contract revenues$95.8M-19% YoY

Decrease in royalty revenue from Hikma due to reduced royalty rate on high-sodium oxybate authorized generic sales.

Largest Expense Items

Research and development$403.5M+9% YoY

Higher clinical studies and outside services costs related to zanidatamab and dordaviprone; personnel expenses increased $17.7M.

Selling, general and administrative$741.9M-15% YoY

Decreased due to Xyrem antitrust litigation settlements of $172M incurred in prior year, offset by increased marketing investment of $22.3M and compensation-related expenses.

Intangible asset amortization$342.3M+8% YoY

Increase primarily due to impact of foreign currency translation on sterling assets.

Cost of product sales (excluding amortization)$250.5M+13% YoY

Higher royalty expenses driven by higher revenues and increased inventory provisions, offset by lower fair value step-up expense of $12.8M.

Watch Items from the Filing

Xywav faces material competition from generic high-sodium oxybate; Amneal and Ascent launched generics in March 2026; Lupin received tentative FDA approval; Tris Pharma filed 505(b)(2) NDA for both Xyrem and Xywav with 22 patent challenges pending.
Three customers represent significant concentration: ESSDS 41%, McKesson 11%, ASD 11% of total revenues; loss of any major distributor could materially impact sales.
Modeyso approval contingent on Phase 3 ACTION confirmatory trial verification; Ziihera accelerated approval dependent on Phase 3 HERIZON-BTC-302 confirmatory trial success; regulatory risk if trials fail.
Substantial debt of $4.4B principal outstanding; 2030 Notes became exchangeable during Q2 2026 (share price condition met); $1.0B principal due 2028 (Tranche B), $1.5B due 2029 (Secured Notes); refinancing risk.
Generated operating cash flow of $823.9M in H1 2026, up 59% YoY; cash and investments of $2.2B with $885M revolving credit facility available; strong liquidity to service debt.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.2B

Net Income

Q2 2026

$192.8M

Free Cash Flow

Q2 2026

$397.6M

ROIC

Q2 2026

9.8%

D/E Ratio

Q2 2026

1.12

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.9% YoY

$4.27BFY 2025

FY22 $3.66BFY23 $3.83BFY24 $4.07BFY25 $4.27B

Net Income

-163.6% YoY

$-356.1MFY 2025

FY22 $-224.1MFY23 $414.8MFY24 $560.1MFY25 $-356.1M

Operating Income

-160.0% YoY

$-430.2MFY 2025

FY22 $-65.5MFY23 $578.6MFY24 $716.6MFY25 $-430.2M

EPS (Diluted)

-167.5% YoY

$-5.84FY 2025

FY22 $-3.58FY23 $6.10FY24 $8.65FY25 $-5.84

Total Assets

-2.9% YoY

$11.66BFY 2025

FY22 $10.84BFY23 $11.39BFY24 $12.01BFY25 $11.66B

Total Debt

+4.0% YoY

$6.39BFY 2025

FY22 $5.76BFY23 $6.32BFY24 $6.14BFY25 $6.39B

Op. Cash Flow

-2.9% YoY

$1.36BFY 2025

FY22 $1.27BFY23 $1.09BFY24 $1.40BFY25 $1.36B

Free Cash Flow

-4.5% YoY

$1.30BFY 2025

FY22 $1.24BFY23 $1.07BFY24 $1.36BFY25 $1.30B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.27B +4.9%	$4.07B +6.1%	$3.83B +4.8%	$3.66B +18.3%	$3.09B +30.9%	$2.36B
Net Income	$-356.1M -163.6%	$560.1M +35.0%	$414.8M +285.1%	$-224.1M +32.0%	$-329.7M -238.2%	$238.6M
Operating Income	$-430.2M -160.0%	$716.6M +23.9%	$578.6M +983.0%	$-65.5M -138.5%	$170.3M -55.0%	$378.1M
EPS (Diluted)	$-5.84 -167.5%	$8.65 +41.8%	$6.10 +270.4%	$-3.58 +35.1%	$-5.52 -230.8%	$4.22
Total Assets	$11.66B -2.9%	$12.01B +5.4%	$11.39B +5.2%	$10.84B -11.9%	$12.30B +88.2%	$6.54B
Total Debt	$6.39B +4.0%	$6.14B -2.8%	$6.32B +9.8%	$5.76B -5.4%	$6.08B +159.7%	$2.34B
Operating Cash Flow	$1.36B -2.9%	$1.40B +27.8%	$1.09B -14.1%	$1.27B +63.4%	$778.5M -13.5%	$899.6M
Free Cash Flow	$1.30B -4.5%	$1.36B +27.1%	$1.07B -14.1%	$1.24B +65.5%	$750.9M -15.1%	$884.6M

Get alerted when JAZZ's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Jazz Pharmaceuticals plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of JAZZ

BlackRock, Inc.
$1.4B5,968,603 sh
FMR LLC
$1.1B4,609,326 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$731.6M3,036,213 sh
VANGUARD CAPITAL MANAGEMENT LLC
$657.8M2,729,650 sh
Capital World Investors
$650.0M2,697,610 sh
LSV ASSET MANAGEMENT
$548.2M2,275,145 sh
FRANKLIN RESOURCES INC
$491.6M2,040,250 sh
STATE STREET CORP
$481.9M1,999,816 sh
DIMENSIONAL FUND ADVISORS LP
$412.9M1,713,592 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$394.8M1,638,544 sh

Fund	Value	Shares
BlackRock, Inc.	$1.4B	5,968,603
FMR LLC	$1.1B	4,609,326
VANGUARD PORTFOLIO MANAGEMENT LLC	$731.6M	3,036,213
VANGUARD CAPITAL MANAGEMENT LLC	$657.8M	2,729,650
Capital World Investors	$650.0M	2,697,610
LSV ASSET MANAGEMENT	$548.2M	2,275,145
FRANKLIN RESOURCES INC	$491.6M	2,040,250
STATE STREET CORP	$481.9M	1,999,816
DIMENSIONAL FUND ADVISORS LP	$412.9M	1,713,592
FULLER & THALER ASSET MANAGEMENT, INC.	$394.8M	1,638,544

Companies Similar to JAZZ

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

EXEL

EXELIXIS, INC.

AI score

Very similar · 21 shared holders

LSV ASSET MANAGEMENT FULLER & THALER ASSET MANAGEMENT, INC.Swedbank AB

UTHR

UNITED THERAPEUTICS Corp

AI score

Very similar · 26 shared holders

Swedbank AB LSV ASSET MANAGEMENT FULLER & THALER ASSET MANAGEMENT, INC.

INCY

INCYTE CORP

AI score

Similar quality profile · 21 shared holders

LSV ASSET MANAGEMENT Swedbank AB Robeco Institutional Asset Management B.V.

DXCM

DEXCOM INC

AI score

Similar quality profile · 16 shared holders

Swedbank AB Tri Locum Partners LP FRONTIER CAPITAL MANAGEMENT CO LLC

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Similar quality profile · 24 shared holders

Swedbank AB PFM Health Sciences, LP LOOMIS SAYLES & CO L P

BSX

BOSTON SCIENTIFIC CORP

AI score

Similar quality profile · 14 shared holders

Capital World Investors Iron Triangle Partners LP Holocene Advisors, LP

BIIB

BIOGEN INC.

AI score

Similar quality profile · 18 shared holders

LSV ASSET MANAGEMENT Swedbank AB PERCEPTIVE ADVISORS LLC

REGN

REGENERON PHARMACEUTICALS, INC.

AI score

Similar quality profile · 21 shared holders

Capital World Investors LSV ASSET MANAGEMENT Swedbank AB

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put JAZZ on your watchlist

Track score changes the day Jazz Pharmaceuticals plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is JAZZ a good stock to buy?

13F Pro's AI-powered analysis of Jazz Pharmaceuticals plc (JAZZ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JAZZ are available on the JAZZ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. JAZZ is classified as a large company.

Which hedge funds own JAZZ?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JAZZ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Jazz Pharmaceuticals plc's investment landscape.